▶ 調査レポート

ヨーロッパ・中東&アフリカの髄膜炎診断検査市場2021年ー2031年:製品種類別(ラテックス凝集試験、イムノフローアッセイ、PCRアッセイ、ELISA検査、培養検査、その他)、パネル種類別、エンドユーザー別

• 英文タイトル:Meningitis Diagnostic Testing Market (Product Type: Latex Agglutination Tests, Lateral Flow Assay, PCR Assay, ELISA Tests, Culture Test, and Others; Panel Type: Syndromic Full Multiplex Panel and Low Plex Panel; and End-user: Hospitals, Diagnostic Centers, and Others) - Europe and Middle East & Africa Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Transparency Market Researchが調査・発行した産業分析レポートです。ヨーロッパ・中東&アフリカの髄膜炎診断検査市場2021年ー2031年:製品種類別(ラテックス凝集試験、イムノフローアッセイ、PCRアッセイ、ELISA検査、培養検査、その他)、パネル種類別、エンドユーザー別 / Meningitis Diagnostic Testing Market (Product Type: Latex Agglutination Tests, Lateral Flow Assay, PCR Assay, ELISA Tests, Culture Test, and Others; Panel Type: Syndromic Full Multiplex Panel and Low Plex Panel; and End-user: Hospitals, Diagnostic Centers, and Others) - Europe and Middle East & Africa Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031 / MRC2204A225資料のイメージです。• レポートコード:MRC2204A225
• 出版社/出版日:Transparency Market Research / 2022年1月
• レポート形態:英文、PDF、281ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥764,940 (USD5,795)▷ お問い合わせ
  Multi User¥1,160,940 (USD8,795)▷ お問い合わせ
  Corporate License¥1,556,940 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Transparency Market Research社の本調査レポートは、ヨーロッパ・中東&アフリカの髄膜炎診断検査市場について調査し、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、製品別分析、種類別分析、エンドユーザー別分析、地域別分析、競争状況などを掲載しています。

Europe and Middle East & Africa Meningitis Diagnostic Testing Market – Scope of ReportTMR’s report on the meningitis diagnostic testing market in EMEA studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2021 to 2031. The report provides revenue of the meningitis diagnostic testing market in EMEA for the period 2017–2031, considering 2020 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the meningitis diagnostic testing market in EMEA from 2021 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the meningitis diagnostic testing market in EMEA.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the meningitis diagnostic testing market in EMEA.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the meningitis diagnostic testing market in EMEA. These serve as valuable tools for existing market players as well as for entities interested in participating in the meningitis diagnostic testing market in EMEA.

The report delves into the competition landscape of the meningitis diagnostic testing market in EMEA. Key players operating in the meningitis diagnostic testing market in EMEA have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the meningitis diagnostic testing market in EMEA profiled in this report.

Key Questions Answered in Europe and Middle East & Africa Meningitis diagnostic testing Market Report
What is the sales/revenue generated by meningitis diagnostic testing across all regions during the forecast period?
What are the opportunities in the meningitis diagnostic testing market in EMEA?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue in EMEA market in 2031?
Which segment is likely to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in EMEA market?
Europe and Middle East & Africa Meningitis Diagnostic Testing Market – Research Objectives and Research Approach
The comprehensive report on the meningitis diagnostic testing market in EMEA begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments are visually appealing to readers. This allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the meningitis diagnostic testing market in EMEA in terms of product type, panel type, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the meningitis diagnostic testing market in EMEA.

レポート目次

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Europe and Middle East & Africa Meningitis Diagnostic Testing Market
4. Market Overview
4.1. Introduction
4.1.1. Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Success Factors for Top Players
5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid /long term impact)
5.3. Key Industry Developments (product launch, product approvals, business expansion, etc.)
5.4. Regulatory Scenario
6. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Product
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, By Product, 2017–2031
6.3.1. Latex Agglutination Tests
6.3.2. Lateral Flow Assay
6.3.3. PCR Assay
6.3.4. ELISA Tests
6.3.5. Culture Test
6.3.6. Others
6.4. Market Attractiveness Analysis, By Product
7. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Type, 2017–2031
7.3.1. Syndromic Full Multiplex Panel
7.3.2. Low Plex Panel
7.4. Market Attractiveness Analysis, By Type
8. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, By End-user, 2017–2031
8.4. Market Attractiveness Analysis, By End-user
9. Europe and Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast, By Region
9.1. Key Findings
9.2. Market Value Forecast, By Region
10. Europe Meningitis Diagnostic Testing Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, By Product, 2017–2031
10.2.1. Latex Agglutination Tests
10.2.2. Lateral Flow Assay
10.2.3. PCR Assay
10.2.4. ELISA Tests
10.2.5. Culture Test
10.2.6. Others
10.3. Market Value Forecast, By Type, 2017–2031
10.3.1. Syndromic Full Multiplex Panel
10.3.2. Low Plex Panel
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Diagnostic Centers
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. Germany
10.5.1.1. Market Value Forecast, by Product, 2017–2031
10.5.1.1.1. Latex Agglutination Tests
10.5.1.1.2. Lateral Flow Assay
10.5.1.1.3. PCR Assay
10.5.1.1.4. ELISA Tests
10.5.1.1.5. Culture Test
10.5.1.1.6. Others
10.5.1.2. Market Value Forecast, by Type, 2017–2031
10.5.1.2.1. Syndromic Full Multiplex Panel
10.5.1.2.2. Low Plex Panel
10.5.1.3. Market Value Forecast, by End-user, 2017–2031
10.5.1.3.1. Hospitals
10.5.1.3.2. Diagnostic Centers
10.5.1.3.3. Others
10.5.2. U.K.
10.5.2.1. Market Value Forecast, by Product, 2017–2031
10.5.2.1.1. Latex Agglutination Tests
10.5.2.1.2. Lateral Flow Assay
10.5.2.1.3. PCR Assay
10.5.2.1.4. ELISA Tests
10.5.2.1.5. Culture Test
10.5.2.1.6. Others
10.5.2.2. Market Value Forecast, by Type, 2017–2031
10.5.2.2.1. Syndromic Full Multiplex Panel
10.5.2.2.2. Low Plex Panel
10.5.2.3. Market Value Forecast, by End-user, 2017–2031
10.5.2.3.1. Hospitals
10.5.2.3.2. Diagnostic Centers
10.5.2.3.3. Others
10.5.3. France
10.5.3.1. Market Value Forecast, by Product, 2017–2031
10.5.3.1.1. Latex Agglutination Tests
10.5.3.1.2. Lateral Flow Assay
10.5.3.1.3. PCR Assay
10.5.3.1.4. ELISA Tests
10.5.3.1.5. Culture Test
10.5.3.1.6. Others
10.5.3.2. Market Value Forecast, by Type, 2017–2031
10.5.3.2.1. Syndromic Full Multiplex Panel
10.5.3.2.2. Low Plex Panel
10.5.3.3. Market Value Forecast, by End-user, 2017–2031
10.5.3.3.1. Hospitals
10.5.3.3.2. Diagnostic Centers
10.5.3.3.3. Others
10.5.4. Italy
10.5.4.1. Market Value Forecast, by Product, 2017–2031
10.5.4.1.1. Latex Agglutination Tests
10.5.4.1.2. Lateral Flow Assay
10.5.4.1.3. PCR Assay
10.5.4.1.4. ELISA Tests
10.5.4.1.5. Culture Test
10.5.4.1.6. Others
10.5.4.2. Market Value Forecast, by Type, 2017–2031
10.5.4.2.1. Syndromic Full Multiplex Panel
10.5.4.2.2. Low Plex Panel
10.5.4.3. Market Value Forecast, by End-user, 2017–2031
10.5.4.3.1. Hospitals
10.5.4.3.2. Diagnostic Centers
10.5.4.3.3. Others
10.5.5. Spain
10.5.5.1. Market Value Forecast, by Product, 2017–2031
10.5.5.1.1. Latex Agglutination Tests
10.5.5.1.2. Lateral Flow Assay
10.5.5.1.3. PCR Assay
10.5.5.1.4. ELISA Tests
10.5.5.1.5. Culture Test
10.5.5.1.6. Others
10.5.5.2. Market Value Forecast, by Type, 2017–2031
10.5.5.2.1. Syndromic Full Multiplex Panel
10.5.5.2.2. Low Plex Panel
10.5.5.3. Market Value Forecast, by End-user, 2017–2031
10.5.5.3.1. Hospitals
10.5.5.3.2. Diagnostic Centers
10.5.5.3.3. Others
10.5.6. Benelux
10.5.6.1. Market Value Forecast, by Product, 2017–2031
10.5.6.1.1. Latex Agglutination Tests
10.5.6.1.2. Lateral Flow Assay
10.5.6.1.3. PCR Assay
10.5.6.1.4. ELISA Tests
10.5.6.1.5. Culture Test
10.5.6.1.6. Others
10.5.6.2. Market Value Forecast, by Type, 2017–2031
10.5.6.2.1. Syndromic Full Multiplex Panel
10.5.6.2.2. Low Plex Panel
10.5.6.3. Market Value Forecast, by End-user, 2017–2031
10.5.6.3.1. Hospitals
10.5.6.3.2. Diagnostic Centers
10.5.6.3.3. Others
10.5.7. Poland
10.5.7.1. Market Value Forecast, by Product, 2017–2031
10.5.7.1.1. Latex Agglutination Tests
10.5.7.1.2. Lateral Flow Assay
10.5.7.1.3. PCR Assay
10.5.7.1.4. ELISA Tests
10.5.7.1.5. Culture Test
10.5.7.1.6. Others
10.5.7.2. Market Value Forecast, by Type, 2017–2031
10.5.7.2.1. Syndromic Full Multiplex Panel
10.5.7.2.2. Low Plex Panel
10.5.7.3. Market Value Forecast, by End-user, 2017–2031
10.5.7.3.1. Hospitals
10.5.7.3.2. Diagnostic Centers
10.5.7.3.3. Others
10.5.8. Norway
10.5.8.1. Market Value Forecast, by Product, 2017–2031
10.5.8.1.1. Latex Agglutination Tests
10.5.8.1.2. Lateral Flow Assay
10.5.8.1.3. PCR Assay
10.5.8.1.4. ELISA Tests
10.5.8.1.5. Culture Test
10.5.8.1.6. Others
10.5.8.2. Market Value Forecast, by Type, 2017–2031
10.5.8.2.1. Syndromic Full Multiplex Panel
10.5.8.2.2. Low Plex Panel
10.5.8.3. Market Value Forecast, by End-user, 2017–2031
10.5.8.3.1. Hospitals
10.5.8.3.2. Diagnostic Centers
10.5.8.3.3. Others
10.5.9. Sweden
10.5.9.1. Market Value Forecast, by Product, 2017–2031
10.5.9.1.1. Latex Agglutination Tests
10.5.9.1.2. Lateral Flow Assay
10.5.9.1.3. PCR Assay
10.5.9.1.4. ELISA Tests
10.5.9.1.5. Culture Test
10.5.9.1.6. Others
10.5.9.2. Market Value Forecast, by Type, 2017–2031
10.5.9.2.1. Syndromic Full Multiplex Panel
10.5.9.2.2. Low Plex Panel
10.5.9.3. Market Value Forecast, by End-user, 2017-2031
10.5.9.3.1. Hospitals
10.5.9.3.2. Diagnostic Centers
10.5.9.3.3. Others
10.5.10. Denmark
10.5.10.1. Market Value Forecast, by Product, 2017–2031
10.5.10.1.1. Latex Agglutination Tests
10.5.10.1.2. Lateral Flow Assay
10.5.10.1.3. PCR Assay
10.5.10.1.4. ELISA Tests
10.5.10.1.5. Culture Test
10.5.10.1.6. Others
10.5.10.2. Market Value Forecast, by Type, 2017–2031
10.5.10.2.1. Syndromic Full Multiplex Panel
10.5.10.2.2. Low Plex Panel
10.5.10.3. Market Value Forecast, by End-user, 2017–2031
10.5.10.3.1. Hospitals
10.5.10.3.2. Diagnostic Centers
10.5.10.3.3. Others
10.5.11. Finland
10.5.11.1. Market Value Forecast, by Product, 2017–2031
10.5.11.1.1. Latex Agglutination Tests
10.5.11.1.2. Lateral Flow Assay
10.5.11.1.3. PCR Assay
10.5.11.1.4. ELISA Tests
10.5.11.1.5. Culture Test
10.5.11.1.6. Others
10.5.11.2. Market Value Forecast, by Type, 2017–2031
10.5.11.2.1. Syndromic Full Multiplex Panel
10.5.11.2.2. Low Plex Panel
10.5.11.3. Market Value Forecast, by End-user, 2017–2031
10.5.11.3.1. Hospitals
10.5.11.3.2. Diagnostic Centers
10.5.11.3.3. Others
10.5.12. Austria
10.5.12.1. Market Value Forecast, by Product, 2017–2031
10.5.12.1.1. Latex Agglutination Tests
10.5.12.1.2. Lateral Flow Assay
10.5.12.1.3. PCR Assay
10.5.12.1.4. ELISA Tests
10.5.12.1.5. Culture Test
10.5.12.1.6. Others
10.5.12.2. Market Value Forecast, by Type, 2017–2031
10.5.12.2.1. Syndromic Full Multiplex Panel
10.5.12.2.2. Low Plex Panel
10.5.12.3. Market Value Forecast, by End-user, 2017–2031
10.5.12.3.1. Hospitals
10.5.12.3.2. Diagnostic Centers
10.5.12.3.3. Others
10.5.13. Switzerland
10.5.13.1. Market Value Forecast, by Product, 2017–2031
10.5.13.1.1. Latex Agglutination Tests
10.5.13.1.2. Lateral Flow Assay
10.5.13.1.3. PCR Assay
10.5.13.1.4. ELISA Tests
10.5.13.1.5. Culture Test
10.5.13.1.6. Others
10.5.13.2. Market Value Forecast, by Type, 2017–2031
10.5.13.2.1. Syndromic Full Multiplex Panel
10.5.13.2.2. Low Plex Panel
10.5.13.3. Market Value Forecast, by End-user, 2017–2031
10.5.13.3.1. Hospitals
10.5.13.3.2. Diagnostic Centers
10.5.13.3.3. Others
10.5.14. Rest of Europe
10.5.14.1. Market Value Forecast, by Product, 2017–2031
10.5.14.1.1. Latex Agglutination Tests
10.5.14.1.2. Lateral Flow Assay
10.5.14.1.3. PCR Assay
10.5.14.1.4. ELISA Tests
10.5.14.1.5. Culture Test
10.5.14.1.6. Others
10.5.14.2. Market Value Forecast, by Type, 2017–2031
10.5.14.2.1. Syndromic Full Multiplex Panel
10.5.14.2.2. Low Plex Panel
10.5.14.3. Market Value Forecast, by End-user, 2017–2031
10.5.14.3.1. Hospitals
10.5.14.3.2. Diagnostic Centers
10.5.14.3.3. Others
10.6. Market Attractiveness Analysis
10.6.1. By Product
10.6.2. By Type
10.6.3. By End-user
10.6.4. By Country
11. Middle East & Africa Meningitis Diagnostic Testing Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product, 2017–2031
11.2.1. Latex Agglutination Tests
11.2.2. Lateral Flow Assay
11.2.3. PCR Assay
11.2.4. ELISA Tests
11.2.5. Culture Test
11.2.6. Others
11.3. Market Value Forecast, by Type, 2017–2031
11.3.1. Syndromic Full Multiplex Panel
11.3.2. Low Plex Panel
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Diagnostic Centers
11.4.3. Others
11.5. Market Value Forecast, by Country, 2017–2031
11.5.1. GCC Countries
11.5.1.1. Market Value Forecast, by Product, 2017–2031
11.5.1.1.1. Latex Agglutination Tests
11.5.1.1.2. Lateral Flow Assay
11.5.1.1.3. PCR Assay
11.5.1.1.4. ELISA Tests
11.5.1.1.5. Culture Test
11.5.1.1.6. Others
11.5.1.2. Market Value Forecast, by Type, 2017–2031
11.5.1.2.1. Syndromic Full Multiplex Panel
11.5.1.2.2. Low Plex Panel
11.5.1.3. Market Value Forecast, by End-user, 2017–2031
11.5.1.3.1. Hospitals
11.5.1.3.2. Diagnostic Centers
11.5.1.3.3. Others
11.5.2. South Africa
11.5.2.1. Market Value Forecast, by Product, 2017–2031
11.5.2.1.1. Latex Agglutination Tests
11.5.2.1.2. Lateral Flow Assay
11.5.2.1.3. PCR Assay
11.5.2.1.4. ELISA Tests
11.5.2.1.5. Culture Test
11.5.2.1.6. Others
11.5.2.2. Market Value Forecast, by Type, 2017–2031
11.5.2.2.1. Syndromic Full Multiplex Panel
11.5.2.2.2. Low Plex Panel
11.5.2.3. Market Value Forecast, by End-user, 2017–2031
11.5.2.3.1. Hospitals
11.5.2.3.2. Diagnostic Centers
11.5.2.3.3. Others
11.5.3. Rest of Middle East & Africa
11.5.3.1. Market Value Forecast, by Product, 2017–2031
11.5.3.1.1. Latex Agglutination Tests
11.5.3.1.2. Lateral Flow Assay
11.5.3.1.3. PCR Assay
11.5.3.1.4. ELISA Tests
11.5.3.1.5. Culture Test
11.5.3.1.6. Others
11.5.3.2. Market Value Forecast, by Type, 2017–2031
11.5.3.2.1. Syndromic Full Multiplex Panel
11.5.3.2.2. Low Plex Panel
11.5.3.3. Market Value Forecast, by End-user, 2017–2031
11.5.3.3.1. Hospitals
11.5.3.3.2. Diagnostic Centers
11.5.3.3.3. Others
11.6. Market Attractiveness Analysis
11.6.1. By Product
11.6.2. By Type
11.6.3. By End-user
11.6.4. By Country
12. Competition Landscape
12.1. Company Profiles
12.1.1. Thermo Fisher Scientific, Inc.
12.1.1.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.1.2. Product Portfolio
12.1.1.3. SWOT Analysis
12.1.1.4. Strategic Overview
12.1.2. BioFire Diagnostics
12.1.2.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.2.2. Product Portfolio
12.1.2.3. SWOT Analysis
12.1.2.4. Strategic Overview
12.1.3. Fast Track Diagnostics Ltd. (FTD) – Siemens Healthineers
12.1.3.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.3.2. Product Portfolio
12.1.3.3. SWOT Analysis
12.1.3.4. Strategic Overview
12.1.4. Bio-Rad Laboratories, Inc.
12.1.4.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.4.2. Product Portfolio
12.1.4.3. SWOT Analysis
12.1.4.4. Strategic Overview
12.1.5. IMMY
12.1.5.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.5.2. Product Portfolio
12.1.5.3. SWOT Analysis
12.1.5.4. Strategic Overview
12.1.6. Nanosphere (Luminex Corporation)
12.1.6.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.6.2. Product Portfolio
12.1.6.3. SWOT Analysis
12.1.6.4. Strategic Overview
12.1.7. Seegene, Inc.
12.1.7.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.7.2. Product Portfolio
12.1.7.3. SWOT Analysis
12.1.7.4. Strategic Overview
12.1.8. Qnostics
12.1.8.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.8.2. Product Portfolio
12.1.8.3. SWOT Analysis
12.1.8.4. Strategic Overview
12.1.9. ELITechGroup
12.1.9.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.9.2. Product Portfolio
12.1.9.3. SWOT Analysis
12.1.9.4. Strategic Overview
12.1.10. Abbott Laboratories
12.1.10.1. Company Overview (HQ, Business Segments, Employee Strength)
12.1.10.2. Product Portfolio
12.1.10.3. SWOT Analysis
12.1.10.4. Strategic Overview
12.1.11. Other Prominent Players

List of Table

Table 01: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by Product Type, 2017–2031

Table 02: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 03: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Size (US$ Mn) Forecast, by End-user, 2017–2031

Table 04: Europe and Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 06: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 07: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-User, 2017–2031

Table 08: Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 09: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 10: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 11: Germany Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 12: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 13: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 14: U.K. Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 15: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 16: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 17: France Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 18: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 19: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 20: Italy Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 21: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 22: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 23: Spain Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 24: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 25: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 26: Benelux Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 27: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 28: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 29: Poland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 30: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 31: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 32: Norway Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 33: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 34: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 35: Sweden Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 36: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 37: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 38: Denmark Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 39: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 40: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 41: Finland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 42: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 43: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 44: Austria Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 45: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 46: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 47: Switzerland Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 48: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 49: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 50: Rest of Europe Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 51: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 52: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 53: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 54: Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 55: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 56: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 57: GCC Countries Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 58: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 59: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 60: South Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 61: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 62: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by Panel Type, 2017–2031

Table 63: Rest of Middle East & Africa Meningitis Diagnostic Testing Market Value (US$ Mn) Forecast, by End-user, 2017–2031